Bellerophon Therapeutics (NASDAQ:BLPH) Shares Pass Below Fifty Day Moving Average of $1.37

Shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.37 and traded as low as $0.75. Bellerophon Therapeutics shares last traded at $0.92, with a volume of 12,571 shares.

Several research analysts have weighed in on BLPH shares. StockNews.com started coverage on shares of Bellerophon Therapeutics in a research report on Tuesday. They set a “sell” rating on the stock. Brookline Capital Acquisition lowered their price target on Bellerophon Therapeutics from $26.00 to $19.00 in a report on Monday, April 4th. Finally, Brookline Capital Management reduced their price objective on Bellerophon Therapeutics from $26.00 to $19.00 in a report on Monday, April 4th.

The stock’s 50 day moving average is $1.37 and its 200 day moving average is $2.10. The stock has a market capitalization of $8.76 million, a price-to-earnings ratio of -0.49 and a beta of -0.15.

Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last announced its quarterly earnings results on Wednesday, May 11th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, sell-side analysts expect that Bellerophon Therapeutics, Inc. will post -2.31 EPS for the current fiscal year.

An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Millennium Management LLC purchased a new position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,243 shares of the biotechnology company’s stock, valued at approximately $59,000. Millennium Management LLC owned about 0.13% of Bellerophon Therapeutics at the end of the most recent reporting period. 12.93% of the stock is owned by institutional investors.

About Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Further Reading